This program is intended for physicians and other healthcare professionals who provide care for patients with HBV monoinfection and HBV/HDV coinfection.
The goal of this activity is to improve participants’ competence in identifying candidates for HBV and HDV therapy and monitoring and managing individuals with HBV and HDV infections.
Upon completion of this activity, participants should be able to:
Identify whether each individual patient with chronic HBV or HBV/HDV infection is or is not currently a candidate for treatment
Appropriately monitor untreated patients with hepatitis B to ensure prompt identification of changes in their status such that treatment becomes appropriate
Appropriately screen for HDV in patients with HBV infections
Select an appropriate treatment regimen for each patient with HBV monoinfection or HBV/HDV coinfection, based on individualized application of clinical practice guidelines
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:
Maria Buti, MD
Professor of Medicine
Hospital Universitario Vall d Hebron
Maria Buti, MD: consultant: Gilead Sciences.
Paul Y. Kwo, MD
Professor of Medicine
Director of Hepatology
Stanford University School of Medicine
Palo Alto, California
Paul Y. Kwo, MD: consultant/advisor/speaker: Aligos, Antios, Assembly, Enanta, Gilead Sciences, Janssen; researcher: Bristol Myers Squibb, Eiger, Gilead Sciences, Janssen, Target Registries; grant support: Altimmune.
Grace LH Wong, MD
Gastroenterology and Hepatology
Assistant Dean (Learning Experience)
CUHK Medical Data Analytics Centre (MDAC)
Faculty of Medicine
The Chinese University of Hong Kong
Hong Kong, China
Grace LH Wong, MD: consultant: AbbVie, Gilead Sciences, and Janssen.
The planners and content peer reviewers from Clinical Care Options, LLC, do not have any relevant financial relationships to disclose
Participation in this self-study activity should be completed in approximately 0.25 hours. To successfully complete this activity and receive credit, learners must follow these steps during the period from March 03, 2023, through June 14, 2024:
1. Create an account or Login at https://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures
3. View and study the content in its entirety
4. Submit answers to the post-test questions and evaluation questions online
You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by clicking the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.
This program has been made available online.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Access to and use of this Interactive Decision Support Tool titled, “Hep B Consult: US, European, and Asian-Pacific Guideline Recommendations on Whether and How to Treat HBV and HDV” is provided subject to the following terms and conditions. PLEASE READ THESE TERMS CAREFULLY.
This Interactive Decision Support Tool is designed to educate healthcare professionals on making optimal management choices for monitoring or treating individuals with HBV and HDV infections. The information provided is based on the AASLD, EASL, and APASL guideline recommendations and expert guidance of Maria Buti, MD, Paul Y. Kwo, MD, Grace LH Wong, MD.
The material published by Clinical Care Options reflects the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the FDA. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
Although the information contained in the “Hep B Consult: US, European, and Asian-Pacific Guideline Recommendations on Whether and How to Treat HBV and HDV” Interactive Decision Support Tool has been produced and processed from sources believed to be reliable, no warranty, expressed or implied, is made regarding the accuracy, adequacy, completeness, legality, reliability, or usefulness of any information. This disclaimer applies to both the isolated and aggregate uses of the information. Clinical Care Options provides this information on an as-is basis. This disclaimer applies to all material published by Clinical Care Options including but not limited to medical information or opinions. All warranties of any kind, expressed or implied, including but not limited to the implied warranties of merchantability, fitness for a particular purpose, freedom from contamination by computer viruses, and noninfringement of proprietary rights are disclaimed.
Any trademarks are the property of respective companies.
© 2023 Clinical Care Options, LLC. All rights reserved.
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Designation of Credit
CCO designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.